FindTrial
Sign In

evaluation of OCTA following antiVEGF in patient having retinal disease non resolving central serous chorioretinopathy

Evaluation of Optical Coherence Tomography Angiography Parameters following use of Anti vascular endothelial growth factor in Non resolving Central Serous Chorioretinopathy - NIl

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/072312
Enrollment
30
Registered
2024-08-12
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H32- Chorioretinal disorders in diseases classified elsewhere

Interventions

Intervention1: Anti Vascular Endothelial Growth Factor: Anti Vascular Endothelial Growth Factor shall be injected intravitreally in patients with non resolving central serous chrioretinopathy and opti

Sponsors

Maulana Azad Medical college
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Treatment naïve subjects in the age group of 25-50 years having non resolving central serous chrioretinopathy of more than four months duration along with subretinal fluid (SRF) involving fovea on optical coherence topography (oct) and active angiographic leakage of fundus fluorescein angiography (FFA) 2)Subject having best corrected visual acuity (BCVA) of at least 6/60

Exclusion criteria

Exclusion criteria: 1)patients having ocular conditions causing accumulation of sub-retinal fluid like diabetic retinopathy,retinal vascular occlusion,ocular inflammation or ocular conditions causing macular exudation such as pathological myopia and antioxidants streaks 2)patients who have undergone any intraocular surgery other than uncomplicated cataract extraction 3)Risk of thrombo-emboli events and/or occurrence within past 6 months

Design outcomes

Primary

MeasureTime frame
Optical coherence tomography angiography parameters including fovea avascular zone,vessel density & choroidal neovascular membrane following anti-vascular endothelial growth factorTimepoint: 1 month—

Secondary

MeasureTime frame
1.Changes in best corrected visual acuity following anti-vascular growth factor 2.Changes in posterior segment optical coherence tomography parameters (Central foveal thickness,sub-coeval choroidal thickness, height of subretinal fluid & pigment epithelial detachment) following anti-vascular growth factor 3.Serum level of vascular endothelial growth factors in subjects of non-resolving central serous chorioretinopathyTimepoint: 1 month—

Countries

India

Contacts

Public ContactDr Miyani Hitenkumar Pravinbhai

Maulana Azad Medical College

miyanihiten10@gmail.com7575019211

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026